KD025: Clinical Trials

6 trials of KD025, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

6 completed. 6 Phase 2.

By phase and status

Phase	Trials	Status
Phase 2	6	Completed 6

Follow KD025: new trials by email Literature Review of KD025 trials Research Report on KD025

Trials (filtered) newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD) BN101 - GVHD, Chronic	Phase 2	Completed	BioNova Pharmaceuticals (Shanghai) LTD.	30	2021-04-27	2024-01-17
A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease Belumosudil (KD025) - Graft vs Host Disease	Phase 2	Completed	Kadmon, a Sanofi Company	54	2016-09-15	2023-06-28
A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis Belumosudil, Placebo - Chronic Plaque Psoriasis	Phase 2	Completed	Kadmon Corporation, LLC	110	2016-09-14	2022-03-16
A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis Belumosudil, BSC - Idiopathic Pulmonary Fibrosis	Phase 2	Completed	Kadmon Corporation, LLC	76	2016-05-26	2022-09-08
Phase 2, Open-label, Study of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-line Therapy KD025 - Psoriasis Vulgaris	Phase 2	Completed	Kadmon Corporation, LLC	38	2014-12-01	2022-05-26
A Safety and Tolerability Study of Belumosudil (KD025) Treatment in Subjects With Moderately Severe Psoriasis Vulgaris Belumosudil - Psoriasis Vulgaris	Phase 2	Completed	Kadmon Corporation, LLC	8	2014-04-01	2022-03-23

Conditions studied

Sponsors

Countries

Top investigators

Results publications